Zobrazeno 1 - 10
of 705
pro vyhledávání: '"Elizabeth A, Mittendorf"'
Autor:
Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A. Mittendorf, Tari A. King, Anna Weiss, Ann H. Partridge, Brittany L. Bychkovsky, Giuseppe Curigliano, Nabihah Tayob, Nancy U. Lin, Judy E. Garber, Sara M. Tolaney, Filipa Lynce
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-6 (2024)
Abstract Following the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast ca
Externí odkaz:
https://doaj.org/article/a6787b2746714e679389db17fc729577
Autor:
Jennifer L. Guerriero, Jia-Ren Lin, Ricardo G. Pastorello, Ziming Du, Yu-An Chen, Madeline G. Townsend, Kenichi Shimada, Melissa E. Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L. Taneja, Otto Metzger, Sara M. Tolaney, Nancy U. Lin, Deborah A. Dillon, Stuart J. Schnitt, Peter K. Sorger, Elizabeth A. Mittendorf, Sandro Santagata
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-22 (2024)
Abstract Emerging data suggests that HER2 intratumoral heterogeneity (ITH) is associated with therapy resistance, highlighting the need for new strategies to assess HER2 ITH. A promising approach is leveraging multiplexed tissue analysis techniques s
Externí odkaz:
https://doaj.org/article/3efb1bd4ddfe4838842869755c17c107
Autor:
Filipa Lynce, Laura E. Stevens, Zheqi Li, Jane E. Brock, Anushree Gulvady, Ying Huang, Faina Nakhlis, Ashka Patel, Jeremy M. Force, Tufia C. Haddad, Naoto Ueno, Vered Stearns, Antonio C. Wolff, Amy S. Clark, Jennifer R. Bellon, Edward T. Richardson, Justin M. Balko, Ian E. Krop, Eric P. Winer, Paulina Lange, E. Shelley Hwang, Tari A. King, Sara M. Tolaney, Alastair Thompson, Gaorav P. Gupta, Elizabeth A. Mittendorf, Meredith M. Regan, Beth Overmoyer, Kornelia Polyak
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-14 (2024)
Abstract Background Patients with inflammatory breast cancer (IBC) have overall poor clinical outcomes, with triple-negative IBC (TN-IBC) being associated with the worst survival, warranting the investigation of novel therapies. Preclinical studies i
Externí odkaz:
https://doaj.org/article/f555191ada5c4d40b9318904da4ff97d
Autor:
Claire B. King, Brittany L. Bychkovsky, Erica T. Warner, Tari A. King, Rachel A. Freedman, Elizabeth A. Mittendorf, Fisher Katlin, Anna Revette, Danielle M. Crookes, Neil Maniar, Lydia E. Pace
Publikováno v:
BMC Primary Care, Vol 24, Iss 1, Pp 1-12 (2023)
Abstract Background Inequitable access to personalized breast cancer screening and prevention may compound racial and ethnic disparities in outcomes. The Breast Cancer Personalized Risk Assessment, Education and Prevention (B-PREP) program, located w
Externí odkaz:
https://doaj.org/article/95864e0a683f4d8bb26581e9f8d32f88
Autor:
Elizabeth A Mittendorf, Sandro Santagata, Jennifer L Guerriero, Jonathan Goldberg, Peter K Sorger, Kelly F Zheng, Daniel E Michaud, Kenichi Shimada, Cheryl Gu, Yvonne X Cui, Esther R Ogayo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/818d9fedfe474b2c916ad911b1f8da12
Autor:
Sara M Tolaney, Tianyu Li, Elizabeth A Mittendorf, Sandro Santagata, Jennifer L Guerriero, Nabihah Tayob, Peter K Sorger, Madeline G Townsend, Kelly F Zheng, Kenichi Shimada, Molly DiLullo, Eileen Wrabel, Tanya Keenan, Romualdo Barroso-Sousa
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/1bff02a4d75c447f9c2d0c663640a8ab
Autor:
Hui Chen, Qingqing Ding, Laila Khazai, Li Zhao, Senthil Damodaran, Jennifer K. Litton, Gaiane M. Rauch, Clinton Yam, Jeffrey T. Chang, Sahil Seth, Bora Lim, Alastair M. Thompson, Elizabeth A. Mittendorf, Beatriz Adrada, Kiran Virani, Jason B. White, Elizabeth Ravenberg, Xingzhi Song, Rosalind Candelaria, Banu Arun, Naoto T. Ueno, Lumarie Santiago, Sadia Saleem, Sausan Abouharb, Rashmi K. Murthy, Nuhad Ibrahim, Mark J. Routbort, Aysegul Sahin, Vicente Valero, William Fraser Symmans, Debu Tripathy, Wei-Lien Wang, Stacy Moulder, Lei Huo
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Recent advances have been made in targeting the phosphoinositide 3-kinase pathway in breast cancer. Phosphatase and tensin homolog (PTEN) is a key component of that pathway. Objective: To understand the changes in PTEN expression over the
Externí odkaz:
https://doaj.org/article/d6308ee798424003bf82ce6d0277871d
Autor:
Alexa S. Zimbalist, Bette J. Caan, Wendy Y. Chen, Elizabeth A. Mittendorf, Deborah A. R. Dillon, Charles Quesenberry, Elizabeth M. Cespedes Feliciano
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Research on the impact of metabolic abnormalities on breast cancer prognosis is limited by small samples and assessment of laboratory values at a single time point, often prior to cancer diagnosis and treatment. In this population
Externí odkaz:
https://doaj.org/article/8fbf556dce84476ba6a374ba6c544350
Autor:
Carlos H. Barrios, Shigehira Saji, Nadia Harbeck, Hong Zhang, Kyung H. Jung, Sheetal Patel, Shilpen Patel, Anh Nguyen Duc, Mario Liste-Hermoso, Stephen Y. Chui, Elizabeth A. Mittendorf
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract Patient-reported outcomes data assessing patients’ experience of immunotherapy treatment burden in potentially curable early-stage triple-negative breast cancer (TNBC) are lacking. These patient-reported data inform clinical benefit and de
Externí odkaz:
https://doaj.org/article/7bdcd76cbfff4bc7bdbcff2271b8e1e3
Autor:
Elizabeth M. Burton, Rodabe N. Amaria, Tina Cascone, Myriam Chalabi, Neil D. Gross, Elizabeth A. Mittendorf, Richard A. Scolyer, Padmanee Sharma, Paolo A. Ascierto
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-11 (2022)
Abstract After the success of immunotherapy in the treatment of advanced metastatic cancer, further evaluation in earlier settings, including high-risk, surgically-resectable disease is underway. Potential benefits of a neoadjuvant immunotherapeutic
Externí odkaz:
https://doaj.org/article/cfb90c8c178541e79522621d06de02ab